News headlines about Masimo (NASDAQ:MASI) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Masimo earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.5143514605697 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s rankings:

Several equities analysts have commented on the stock. Zacks Investment Research cut shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BidaskClub cut shares of Masimo from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $108.00 target price on shares of Masimo in a research report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $97.17.

Masimo (NASDAQ:MASI) traded down $0.03 during trading hours on Wednesday, hitting $86.61. 461,751 shares of the company were exchanged, compared to its average volume of 460,791. The company has a market cap of $4,480.00, a PE ratio of 13.73, a PEG ratio of 3.28 and a beta of 0.72. Masimo has a 52 week low of $70.48 and a 52 week high of $104.71.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.17. The company had revenue of $193.69 million for the quarter, compared to analysts’ expectations of $189.01 million. Masimo had a net margin of 45.83% and a return on equity of 22.17%. Masimo’s revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.52 EPS. research analysts expect that Masimo will post 2.95 EPS for the current fiscal year.

In related news, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total value of $900,000.00. Following the sale, the director now owns 73,249 shares of the company’s stock, valued at approximately $6,592,410. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Yongsam Lee sold 5,000 shares of Masimo stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $89.89, for a total transaction of $449,450.00. Following the completion of the sale, the executive vice president now directly owns 74,000 shares in the company, valued at approximately $6,651,860. The disclosure for this sale can be found here. Insiders sold a total of 63,074 shares of company stock worth $5,618,945 in the last ninety days. 13.10% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/17/masimo-masi-given-news-sentiment-rating-of-0-21.html.

About Masimo

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.